✓ Betalning med kreditkort återställd — säker kassahantering via Privacy Shield

Dinex Ec

Dinex EC (Didanosine 250/400 mg) — Cipla older NRTI for HIV. Reserved for salvage therapy. FDA black-box pancreatitis, lactic acidosis, and peripheral neuropathy warnings.

Artikelnummer: Dinex Ec Kategori: , , Tagg:

Medicinskt granskad av Morgan Ellis — Apoteksforskare · 8 års erfarenhet  · Senast granskad: maj 2026

Krypterad kassa
Kryptobetalning ger 10% rabatt
Diskret världsomspännande leverans
1 400+ kunder · 50+ länder

Denna produkt är för närvarande slut i lager och inte tillgänglig.

Quick Answer

Dinex EC — didanosine 250/400 mg enteric-coated capsule (Cipla). NRTI for HIV — older agent, now reserved for salvage therapy or settings where modern NRTIs are unavailable. Mitochondrial toxicity (peripheral neuropathy, pancreatitis, lactic acidosis) limits use.

Vad du får med MedsBase:

  • WHO-GMP-certifierad tillverkare
  • Diskret förpackning i vanligt kuvert
  • Världsvid leverans
  • Betygsatt av 1 400+ kunder (läs recensioner)

📦 Reshipment Assurance: om din order inte har anlänt 20 arbetsdagar efter försändelse, skickar vi en ny utan extra kostnad. Läs policyn.

Varför beställa från MedsBase

Dinex EC ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.

FDA black-box: pancreatitis + lactic acidosis
Didanosine carries multiple black-box warnings: fatal lactic acidosis with hepatic steatosis (especially with stavudine or in pregnancy), severe pancreatitis (5-7% incidence — fatal cases reported), peripheral neuropathy (12-34%), retinal changes/optic neuritis. Modern HIV care has largely retired didanosine.

Vanliga frågor

Why is didanosine still used?

Resource-limited settings, salvage regimens after multiple-drug-resistant HIV, or specific historical situations. Modern guidelines use TDF or TAF (or abacavir) + lamivudine/emtricitabine instead — much better safety profile.

Pancreatitis warning?

5-7% develop pancreatitis. Stop immediately if abdominal pain + raised amylase/lipase. Avoid combining with other pancreatitis-risk drugs (alcohol, valproate, hypertriglyceridaemia).

Peripheral neuropathy?

Common (12-34%) and dose-related. Usually reversible if drug stopped early. Stavudine combination compounds risk — never combine d4T + ddI.

Lactic acidosis?

Mitochondrial toxicity feature. More common with d4T+ddI combination, in women, in pregnancy, in obesity. Symptoms: malaise, fatigue, abdominal pain, breathlessness, nausea. Stop drug immediately.

Läkemedelsinteraktioner?

Tenofovir + didanosine raises ddI levels — avoid combination or reduce ddI dose. Allopurinol raises ddI levels (avoid). Methadone reduces ddI levels (clinically minor).

Graviditet?

Avoid in pregnancy due to lactic acidosis risk (especially with d4T).

Vad händer om jag missar en dos?

Take when you remember if same day; otherwise skip. Do not double up. Adherence is critical — and this drug is hard to take consistently due to food restrictions and side effects.

Empty stomach?

Older formulations needed empty stomach; the EC formulation is taken on an empty stomach (1 hour before or 2 hours after a meal) — food reduces absorption ~50%.

When should it be stopped?

Severe pancreatitis (any), peripheral neuropathy progression, lactic acidosis, retinal changes, or virological failure all mandate stopping or substituting. Most patients on ddI in modern care should be discussed with HIV specialist for switch to safer alternatives.

Long-term outlook?

Almost all HIV patients in modern care should be on a TDF or TAF or abacavir-based regimen with INSTI third agent. Continued ddI use should be reviewed at every clinic visit with a clear plan to switch when safer alternatives become available.

Other HIV & Antiviral Medications

  • Trioday — TDF + 3TC + EFV — single-tablet regimen by Cipla
  • Triomune — d4T + 3TC + NVP — older 3-in-1 (stavudine-based)
  • Zepdon — raltegravir 400 mg — integrase inhibitor
  • Abamune L — abacavir + lamivudine — alternative NRTI backbone
  • Tenvir L — tenofovir + lamivudine — alternative NRTI backbone
Medicinsk ansvarsfriskrivning: HIV treatment is a complex, lifelong therapy. Drug choice depends on genotype, resistance testing, comorbidities, and prior treatment history. Discuss any regimen change with an HIV specialist. Adherence >95% is required to prevent resistance. Test for HBV before starting any tenofovir-, lamivudine-, or emtricitabine-containing regimen — withdrawal can cause severe HBV flare in co-infected patients.

More options in HIV Medication

Rangerade efter senaste ordervolym på MedsBase — vad andra kunder i denna kategori väljer.

Styrka

250 mg, 400 mg

Kvantitet

30 Tablett/er, 60 Tablett/er, 90 Tablett/er

Farmaceutisk form

Tabletter

Tillverkare

Cipla Inc

Behandling

HIV Infection

Generiskt märke

Didanosine

Recensioner

Det finns inga recensioner än

Skriv en recension
Dinex Ec Dinex Ec
Betyg*
0/5
* Betyg är obligatoriskt
* Svar är obligatoriskt
Din recension
* Recension är obligatorisk
Namn
* Namn är obligatoriskt
Lägg till foton eller video i din recension

Frågor & svar

Ställ en fråga
Dinex Ec Dinex Ec
Din fråga
* Fråga är obligatorisk
Namn
* Namn är obligatoriskt
Det finns inga frågor än